Dr. Nalini Kanta Sahoo is a well-known academic and researcher in the field of Pharmaceutical Analysis. He is currently the Director and Professor at MIT College of Pharmacy, Moradabad, Uttar Pradesh, under Dr. A.P.J. Abdul Kalam Technical University. The college is NBA accredited and NAAC A+ approved. He holds a Ph.D. and M.Pharm in Pharmaceutical Analysis and Quality Assurance and has completed a Post-Doctoral Fellowship in Vietnam. He also received training in Pharmacovigilance from the Uppsala Monitoring Centre, Sweden.
Dr. Sahoo has a strong research profile with over 700 citations on Google Scholar, an h-index of 12, and a ResearchGate score of 25.88. He has held research positions in Egypt, Malaysia, and China and is actively involved in global academic organizations such as YGMRO in Chennai and Bentham Science Publishers.
He serves in several advisory roles including as a board member of the World Leadership Academy and the Foundation for Health and Environmental Research. He is also President of the Indian Pharma Educational Society (Central Zone, Telangana), advisor to student and research networks, and Chief Editor of Research Edit. He consults for healthcare companies, acts as an examiner for universities, and writes scientific content for international platforms.
Dr. Sahoo is dedicated to promoting high-quality research, education, and collaboration in the pharmaceutical field.
Development of new biomarkers and early prognosis of drug induced hepatotoxicity through metabolomic approaches
Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage. Drug-induced liver injury is a cause of acute and chronic liver disease.The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents. Certain medicinal agents, when taken in overdoses and sometimes even when introduced within therapeutic ranges, may injure the organ. Other chemical agents, such as those used in laboratories and industries, natural chemicals (e.g., microcystins) and herbal remedies can also induce hepatotoxicity. Chemicals that cause liver injury are called hepatotoxins.
Drug-induced hepatotoxicity is a potentially fatal adverse effect and the leading cause of acute liver failure in most of the countries. The liver can be affected directly, in a dose-dependent manner, or idiosyncratically, independently of the dose, and therefore unpredictable. Currently, hepatotoxicity is a diagnosis of exclusion that physicians should suspect in patients with unexplained elevation of liver enzymes. Therefore, new diagnostic biomarkers are necessary to improve the prognosis of hepatotoxicity. Although several biomarkers have been found through various analytical and genetic approaches, none of them have been able to display enough specificity and sensitivity, so new approaches are needed. Targeted metabolomics aims to analyze a set of pre-selected metabolites from biologically relevant metabolic pathways. In this sense, metabolomics approaches using sophisticated instruments like NMR is a strongly and promising emerging field which is achieved from biofluids collected through minimally invasive procedures (either SPE or LLE or Ppt or ABE), can obtain early biomarkers of toxicity, which may constitute specific indicators of hepatotoxicity.
These biomarkers can be mainly identified and qualified in rat but also for humans, several biomarkers will be described and will be validated, followed by future (pre-) clinical routine application. NMR based metabolomics , is able to acquire data from multiple types of biological samples such as bacteria, cultured mammalian cells, animal tissues and biofluids (e.g., serum and urine). Finally, the Bioinformatics softwares can automatically process the generated large-scale data set with high efficiency.
Key words: NMR, Metabolomics; hepatotoxicity; bioinformatics tools